Back to search
High-Risk Neuroblastoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which High-Risk Neuroblastoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which High-Risk Neuroblastoma trials you may qualify forThis phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, r…
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage…
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with t…
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard ther…
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24…
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.…
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine, may carry radiation directly to tumor cells and not harm normal cells. Drugs used in…